Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient's body to target CD20-expressing malignant B cells PHILADELPHIA, Oct.

The posters are available on the Posters and Publications page of the Company’s website.

The global Oncolytic Virus Cancer Therapy (OVT) market is expected to be valued at USD 22.86 million in 2023, with ...

states a FMI analyst Key players in the oncolytic adenovirus market are Amgen, Sorrento Therapeutics, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, CG Oncology ...

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

It is Transgene's second most advanced neoantigen immunotherapy programme after TG4050 for head and neck cancer, which is in ...

Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.

Transgene announced that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in ...

Shares of French biotech Transgene (tumbled 13.5% to 1.01 euros by late morning after it announced that its randomized Phase ...

Transgene’s therapeutic cancer vaccine candidate has failed a mid-stage test in certain HPV-driven cancers, sending its ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...